Shanghai, Shanghai, China The venture was found in Asia in China. The leading representative office of defined VC is situated in the Shanghai.
The fund has no exact preference in a number of founders of portfolio startups. For fund there is a match between the location of its establishment and the land of its numerous investments - China. Among the most popular fund investment industries, there are Financial Services, Mobile Apps. Among the most popular portfolio startups of the fund, we may highlight Bilibili, Shanghai Henlius, GeneCast Biotechnology. Besides, a startup needs to be aged 6-10 years to get the investment from the fund.
The top amount of exits for fund were in 2018. The common things for fund are deals in the range of 50 - 100 millions dollars. The fund is constantly included in 2-6 investment rounds annually. When the investment is from Loyal Valley Capital the average startup value is more than 1 billion dollars. The important activity for fund was in 2019. Comparing to the other companies, this Loyal Valley Capital performs on 4 percentage points more the average number of lead investments. Speaking about the real fund results, this VC is 13 percentage points more often commits exit comparing to other organizations.
The standard case for the fund is to invest in rounds with 4-5 partakers. Despite the Loyal Valley Capital, startups are often financed by Shenzhen Capital Group, TriWise Capital, Tencent Holdings. The meaningful sponsors for the fund in investment in the same round are Tencent Holdings, CITIC Capital Holdings, CICC. In the next rounds fund is usually obtained by Tencent Holdings, CITIC Capital Holdings, Bertelsmann Asia Investments.
The overall number of key employees were 4.
Related Funds
| Fund Name | Location |
| Blackmont Capital | Canada, Ontario, Toronto |
| Braincapital | - |
| Bright Link Ventures | England, London, United Kingdom |
| Chinergy Capital | Anhui, China, Wuxi |
| CNBB Venture Partners | Rotterdam, The Netherlands, Zuid-Holland |
| Crossover | Austin, Texas, United States |
| Greenspace | Canada, Ontario, Toronto |
| OTF Jasoor Ventures | Masqat, Muscat, Oman |
| Soliton | China, Huangpu, Shanghai |
| The New York Times | New York, New York, United States |
Notable deals
| Company | Industry | Round Size | Date | Investors | Location |
Core Medical Technology | $30M | 17 Apr 2023 | Shenzhen, Guangdong, China | ||
Surgerii Technology | 04 Apr 2023 | Haidian District, Beijing, China | |||
Bowang Pharmaceutical | $61M | 23 Mar 2023 | Jiading, Shanghai, China | ||
Zhishan Weixin Biotechnology | $309K | 01 Feb 2023 | Chengdu, Sichuan, China | ||
Jinyuansheng | $154M | 15 Aug 2022 | Shanghai, Shanghai, China | ||
Medilink Therapeutics | $70M | 14 Mar 2022 | Gusu District, Jiangsu, China | ||
Peijie Hotpot | $15M | 17 Jan 2022 | Jiangbei, Chongqing, China | ||
Sciwind Biosciences | $69M | 11 Oct 2021 | Shangcheng District, Zhejiang, China | ||
Leads Biolabs | $100M | 08 Oct 2021 | Nanjing, Jiangsu, China |
– Arctic Vision is a Shangai, China-based clinical-stage ophthalmology company focused on developing innovative therapies for pan-ocular diseases.
– The company closed an over US$100m Series B financing.
– The round was led by Loyal Valley Capital, with participation from Tencent, Octagon Capital, and Dr. Adrian Cheng.
– The proceeds will continue to support the progress of Arctic Vision’s pipeline, including clinical developments, registrational activities, and commercialization; as well as the establishment of in-house R&D capabilities; business development, and organizational growth.
– Medilink Therapeutics Raises $50 Million in Series A Financing To Accelerate Next-Generation Conjugated Drugs Research & Development
– The financing includes a series-A1 round led by Apricot Capital, and a series-A2 round co-led by Loyal Valley Capital and Qiming Venture Partners.
– Medilink Therapeutics was established in 2020 by a sophisticated team of industrial veterans.
– Medilink has high ambitions for its ADC R&D to be globally competitive, and meet the needs of global patients in the future.
1. You post comments at your own choice and risk. You bear the whole responsibility,related to their substance, content and the fact of publication. We shall not bear anyliability in respect of such comments.
2. While commenting, you shall use only actual, truthful and confirmed data. In thesame time you shall not use vulgar, abusive or defamatory language as well as expresshatred or call to violence or cruelty.
3. We do not intend to delete any comments on the website unless within our “noticeand take down” procedure.
4. We can moderate comments at any time.
5. While commenting, you are under the rule of our website’s terms of use and privacypolicy.
6. We retain our right to delete any comment or any other content of the website at ourwill in case we know or suppose such content is illegal or breaches any lawful right.
Review
- No reviews are submitted yet.
Sign up and get access to full fund profile and advanced analysis.
Full teamIndustries heatmapStages heatmapGeorgaphy breakdownCoinvestorsPortfolio analysisPerformance indexesLatest highlights
Unlock all data Latest deals
| Company | Industry | Round Size | Date | Investors | Location |
Core Medical Technology | $30M | 17 Apr 2023 | Shenzhen, Guangdong, China | ||
Surgerii Technology | 04 Apr 2023 | Haidian District, Beijing, China | |||
Bowang Pharmaceutical | $61M | 23 Mar 2023 | Jiading, Shanghai, China | ||
Zhishan Weixin Biotechnology | $309K | 01 Feb 2023 | Chengdu, Sichuan, China | ||
Jinyuansheng | $154M | 15 Aug 2022 | Shanghai, Shanghai, China | ||
Medilink Therapeutics | $70M | 14 Mar 2022 | Gusu District, Jiangsu, China | ||
Peijie Hotpot | $15M | 17 Jan 2022 | Jiangbei, Chongqing, China | ||
Sciwind Biosciences | $69M | 11 Oct 2021 | Shangcheng District, Zhejiang, China | ||
Leads Biolabs | $100M | 08 Oct 2021 | Nanjing, Jiangsu, China |
